BioCentury | Sep 29, 2014
Company News

Ligand, CURx Pharmaceuticals deal

...expanded an August 2013 deal with CURx to include the development and commercialization of Ligand's Captisol-enabled lamotrigine...
...million in milestones plus revenue from sales of Captisol and tiered royalties of 4-7% on Captisol-enabled lamotrigine...
Items per page:
1 - 1 of 1